Use filters to refine the search results.
Results 1-4 of 4
|30-Apr-2018||Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial||Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L, et al|
|3-May-2018||Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis||Brown, R; Curry, E; Zeller, C; Masrour, N; Patten, D, et al|
|19-Apr-2018||The surgical intelligent knife distinguishes normal, borderline and malignant gynaecological tissues using rapid evaporative ionisation mass spectrometry (REIMS)||Phelps, DL; Balog, J; Gildea, LF; Bodai, Z; El-Bahrawy, MA, et al|
|3-May-2018||Biomarker assessment of HR deficiency, tumor BRCA1/2 mutations and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy||Stronach, EA; Paul, J; Timms, KM; Hughes, E; Brown, K, et al|